Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial

Launched by YONSEI UNIVERSITY · Jan 6, 2019

Keywords

ClinConnect Summary

The T-PASS trial is studying whether a medication called ticagrelor, when taken alone, can effectively prevent blood clots in patients who have received a specific type of heart stent after experiencing an acute coronary syndrome (ACS) event, such as a heart attack or unstable angina. The trial aims to see if using only ticagrelor is just as effective as combining it with aspirin, while also reducing the risk of bleeding. Participants will be randomly assigned to either continue taking both medications for a year or to stop taking aspirin after a month, allowing researchers to compare the safety and effectiveness of these two approaches.

To be eligible for the trial, participants must be at least 19 years old and have received a new type of heart stent called an Orsiro stent for treating ACS. However, people over 80, those with certain bleeding risks or conditions requiring other blood-thinning medications, pregnant women, and individuals with a life expectancy of less than one year are not eligible. Participants will need to provide informed consent, meaning they agree to take part with a full understanding of the study. Throughout the trial, patients can expect regular check-ups to monitor their health and the effectiveness of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients ≥19 years old
• • 2. Patients who received new generation sirolimus-eluting (Orsiro® series) stent implantation for treating ACS, including acute MI and unstable angina
• • 3. Provision of informed consent
• Exclusion Criteria:
• • 1. Age\> 80 years
• • 2. Increased risk of bleeding, anemia, thrombocytopenia
• • 3. A need for oral anticoagulation therapy
• • 4. Pregnant women or women with potential childbearing
• • 5. Life expectancy \< 1 year